Skip to main content
SpringerLink
Log in

Safety and Efficacy of Thrombolysis with Intravenous Alteplase in Older Stroke Patients

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Stroke is a common cause of death and persisting disability worldwide, and thrombolysis with intravenous alteplase is the only approved treatment for acute ischaemic stroke. Older age is the most important non-modifiable risk factor for stroke, and demographic changes are also resulting in an increasingly ageing population. However, clinical trial evidence for the use of intravenous alteplase is limited for the older age group where stroke incidence is highest. In this article, the current evidence regarding the safety and efficacy of intravenous thrombolytic therapy in stroke patients aged ≥80 years is critically analysed and the gap in current knowledge highlighted. In summary, intravenous thrombolysis in stroke patients aged ≥80 years seems to be associated with less favourable clinical outcomes and higher mortality than in younger patients, which is consistent with the natural course in untreated patients. The risk of symptomatic intracranial haemorrhage does not appear to be significantly higher in the elderly group, suggesting that intracranial bleeding complications are unlikely to outweigh the potential benefit in this age group. Overall, withholding thrombolytic treatment in ischaemic stroke on the basis of advanced age alone is no longer justifiable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Di Carlo A. Human and economic burden of stroke. Age Ageing. 2009;38(1):4–5.

    Article  PubMed  Google Scholar 

  2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063):1436–42.

    Article  PubMed  CAS  Google Scholar 

  3. Sturm JW, Donnan GA, Dewey HM, Macdonell RA, Gilligan AK, Srikanth V, et al. Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2004;35(10):2340–5.

    Article  PubMed  Google Scholar 

  4. Sanossian N, Ovbiagele B. Prevention and management of stroke in very elderly patients. Lancet Neurol. 2009;8(11):1031–41.

    Article  PubMed  Google Scholar 

  5. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005;366(9499):1773–83.

    Article  PubMed  CAS  Google Scholar 

  6. Rojas JI, Zurru MC, Romano M, Patrucco L, Cristiano E. Acute ischemic stroke and transient ischemic attack in the very old: risk factor profile and stroke subtype between patients older than 80 years and patients aged less than 80 years. Eur J Neurol. 2007;14(8):895–9.

    Article  PubMed  CAS  Google Scholar 

  7. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2(1):43–53.

    Article  PubMed  Google Scholar 

  8. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics: 2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25–146.

    Article  PubMed  Google Scholar 

  9. Krug EG, Mercy JA, Dahlberg LL, Zwi AB. The world report on violence and health. Lancet. 2002;360(9339):1083–8.

    Article  PubMed  Google Scholar 

  10. Powell JL, Cook IG. Global ageing in comparative perspective: a critical discussion. Int J Soc Policy. 2009;29:388–400.

    Article  Google Scholar 

  11. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007;6(2):182–7.

    Article  PubMed  Google Scholar 

  12. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7.

    Article  Google Scholar 

  13. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol. 2004;61(7):1066–70.

    Article  PubMed  Google Scholar 

  14. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–82.

    Article  PubMed  CAS  Google Scholar 

  15. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.

    Article  PubMed  CAS  Google Scholar 

  16. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–74.

    Article  PubMed  Google Scholar 

  17. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009;40(7):2438–41.

    Article  PubMed  CAS  Google Scholar 

  18. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009(4):CD000213.

  19. Derex L, Nighoghossian N. Thrombolysis, stroke-unit admission and early rehabilitation in elderly patients. Nat Rev Neurol. 2009;5(9):506–11.

    Article  PubMed  Google Scholar 

  20. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017–25.

    Article  PubMed  CAS  Google Scholar 

  21. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352(9136):1245–51.

    Article  PubMed  CAS  Google Scholar 

  22. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282(21):2019–26.

    Article  PubMed  CAS  Google Scholar 

  23. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276 g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke. 2000;31(4):811–6.

    Article  PubMed  CAS  Google Scholar 

  24. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997;28(11):2109–18.

    Article  Google Scholar 

  25. No authors listed. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997;28(11):2119–25.

    Article  Google Scholar 

  26. IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial [published erratum appears in Lancet 2012 Aug 25;380(9843):730]. Lancet. 2012;379(9834):2352–63.

    Google Scholar 

  27. Engelter ST, Reichhart M, Sekoranja L, Georgiadis D, Baumann A, Weder B, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology. 2005;65(11):1795–8.

    Article  PubMed  CAS  Google Scholar 

  28. Mouradian MS, Senthilselvan A, Jickling G, McCombe JA, Emery DJ, Dean N, et al. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry. 2005;76(9):1234–7.

    Article  PubMed  CAS  Google Scholar 

  29. van Oostenbrugge RJ, Hupperts RM, Lodder J. Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre. J Neurol Neurosurg Psychiatry. 2006;77(3):375–7.

    Article  PubMed  Google Scholar 

  30. Parnetti L, Silvestrelli G, Lanari A, Tambasco N, Capocchi G, Agnelli G. Efficacy of thrombolytic (rt-PA) therapy in old stroke patients: the Perugia Stroke Unit experience. Clin Exp Hypertens. 2006;28(3–4):397–404.

    Article  PubMed  CAS  Google Scholar 

  31. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry. 2006;77(7):826–9.

    Article  PubMed  CAS  Google Scholar 

  32. Ringleb PA, Schwark C, Kohrmann M, Kulkens S, Juttler E, Hacke W, et al. Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. J Neurol Neurosurg Psychiatry. 2007;78(7):690–3.

    Article  PubMed  CAS  Google Scholar 

  33. Uyttenboogaart M, Schrijvers EM, Vroomen PC, De Keyser J, Luijckx GJ. Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience. Age Ageing. 2007;36(5):577–9.

    Article  PubMed  Google Scholar 

  34. Gomez-Choco M, Obach V, Urra X, Amaro S, Cervera A, Vargas M, et al. The response to IV rt-PA in very old stroke patients. Eur J Neurol. 2008;15(3):253–6.

    Article  PubMed  CAS  Google Scholar 

  35. Meseguer E, Labreuche J, Olivot JM, Abboud H, Lavallee PC, Simon O, et al. Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review. Age Ageing. 2008;37(1):107–11.

    Article  PubMed  Google Scholar 

  36. Pundik S, McWilliams-Dunnigan L, Blackham KL, Kirchner HL, Sundararajan S, Sunshine JL, et al. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke. J Stroke Cerebrovasc Dis. 2008;17(5):266–72.

    Article  PubMed  Google Scholar 

  37. Toni D, Lorenzano S, Agnelli G, Guidetti D, Orlandi G, Semplicini A, et al. Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy. Cerebrovasc Dis. 2008;25(1–2):129–35.

    Article  PubMed  CAS  Google Scholar 

  38. Ford GA, Ahmed N, Azevedo E, Grond M, Larrue V, Lindsberg PJ, et al. Intravenous alteplase for stroke in those older than 80 years old. Stroke. 2010;41(11):2568–74.

    Article  PubMed  Google Scholar 

  39. Boulouis G, Dumont F, Cordonnier C, Bodenant M, Leys D, Henon H. Intravenous thrombolysis for acute cerebral ischaemia in old stroke patients >/=80 years of age. J Neurol. 2012;259(7):1461–7.

    Article  PubMed  Google Scholar 

  40. Dharmasaroja PA, Muengtaweepongsa S, Dharmasaroja P. Intravenous thrombolysis in Thai patients with acute ischemic stroke: role of aging. J Stroke Cerebrovasc Dis. (Epub 2011 Dec 14).

  41. Costello CA, Campbell BC. Perez de la Ossa N, Zheng TH, Sherwin JC, Weir L, et al. Age over 80 years is not associated with increased hemorrhagic transformation after stroke thrombolysis. J Clin Neurosci. 2012;19(3):360–3.

    Article  PubMed  CAS  Google Scholar 

  42. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105(14):1679–85.

    Article  PubMed  CAS  Google Scholar 

  43. Mateen FJ, Buchan AM, Hill MD. Outcomes of thrombolysis for acute ischemic stroke in octogenarians versus nonagenarians. Stroke. 2010;41(8):1833–5.

    Article  PubMed  Google Scholar 

  44. Sarikaya H, Arnold M, Engelter ST, Lyrer PA, Michel P, Odier C, et al. Intravenous thrombolysis in nonagenarians with ischemic stroke. Stroke. 2011;42(7):1967–70.

    Article  PubMed  Google Scholar 

  45. Breuer L, Blinzler C, Huttner HB, Kiphuth IC, Schwab S, Kohrmann M. Off-label thrombolysis for acute ischemic stroke: rate, clinical outcome and safety are influenced by the definition of ‘minor stroke’. Cerebrovasc Dis. 2011;32(2):177–85.

    Article  PubMed  CAS  Google Scholar 

  46. Guillan M, Alonso-Canovas A, Garcia-Caldentey J, Sanchez-Gonzalez V, Hernandez-Medrano I, Defelipe-Mimbrera A, et al. Off-label intravenous thrombolysis in acute stroke. Eur J Neurol. 2012;19(3):390–4.

    Article  PubMed  CAS  Google Scholar 

  47. Meretoja A, Putaala J, Tatlisumak T, Atula S, Artto V, Curtze S, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke. 2010;41(7):1450–8.

    Article  PubMed  Google Scholar 

  48. Rubiera M, Ribo M, Santamarina E, Maisterra O, Delgado-Mederos R, Delgado P, et al. Is it time to reassess the SITS-MOST criteria for thrombolysis? A comparison of patients with and without SITS-MOST exclusion criteria. Stroke. 2009;40(7):2568–71.

    Article  PubMed  Google Scholar 

  49. The SITS-EAST Collaborative Group. Intravenous alteplase in ischemic stroke patients not fully adhering to the current drug license in Central and Eastern Europe. Int J Stroke. 2012;7(8):615–22.

    Google Scholar 

  50. Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of > or =80 versus <80 years of age: a systematic review across cohort studies. Age Ageing. 2006;35(6):572–80.

    Article  PubMed  Google Scholar 

  51. Di Carlo A, Lamassa M, Pracucci G, Basile AM, Trefoloni G, Vanni P, et al. Stroke in the very old: clinical presentation and determinants of 3-month functional outcome. A European perspective. European BIOMED Study of Stroke Care Group. Stroke. 1999;30(11):2313–9.

    Article  PubMed  Google Scholar 

  52. Bhatnagar P, Sinha D, Parker RA, Guyler P, O’Brien A. Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age. J Neurol Neurosurg Psychiatry. 2011;82(7):712–7.

    Article  PubMed  Google Scholar 

  53. Wardlaw JM, Murray V, Berge E, Del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379(9834):2364–72.

    Google Scholar 

  54. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7(4):299–309.

    Article  PubMed  Google Scholar 

  55. Marini C, Baldassarre M, Russo T, De Santis F, Sacco S, Ciancarelli I, et al. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology. 2004;62(1):77–81.

    Article  PubMed  CAS  Google Scholar 

  56. Fonarow GC, Reeves MJ, Zhao X, Olson DM, Smith EE, Saver JL, et al. Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke. Circulation. 2010;121(7):879–91.

    Article  PubMed  Google Scholar 

  57. Saposnik G, Hill MD, O’Donnell M, Fang J, Hachinski V, Kapral MK. Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke. Stroke. 2008;39(8):2318–24.

    Article  PubMed  Google Scholar 

  58. Palnum KD, Petersen P, Sorensen HT, Ingeman A, Mainz J, Bartels P, et al. Older patients with acute stroke in Denmark: quality of care and short-term mortality. A nationwide follow-up study. Age Ageing. 2008;37(1):90–5.

    Article  PubMed  Google Scholar 

  59. Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke. 2007;38(6):1873–80.

    Article  PubMed  Google Scholar 

  60. Collins TC, Petersen NJ, Menke TJ, Souchek J, Foster W, Ashton CM. Short-term, intermediate-term, and long-term mortality in patients hospitalized for stroke. J Clin Epidemiol. 2003;56(1):81–7.

    Article  PubMed  Google Scholar 

  61. Asplund K, Carlberg B, Sundstrom G. Stroke in the elderly: observations in a population-based sample of hospitalized patients. Cerebrovasc Dis. 1992;2(3):152–7.

    Article  Google Scholar 

  62. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147(9):1561–4.

    Article  PubMed  CAS  Google Scholar 

  63. Bamford J, Dennis M, Sandercock P, Burn J, Warlow C. The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project. J Neurol Neurosurg Psychiatry. 1990;53(10):824–9.

    Article  PubMed  CAS  Google Scholar 

  64. Sharma JC, Fletcher S, Vassallo M. Strokes in the elderly—higher acute and 3-month mortality—an explanation. Cerebrovasc Dis. 1999;9(1):2–9.

    Article  PubMed  CAS  Google Scholar 

  65. Steger C, Pratter A, Martinek-Bregel M, Avanzini M, Valentin A, Slany J, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J. 2004;25(19):1734–40.

    Article  PubMed  Google Scholar 

  66. Kammersgaard LP, Jorgensen HS, Reith J, Nakayama H, Pedersen PM, Olsen TS. Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study. Age Ageing. 2004;33(2):149–54.

    Article  PubMed  Google Scholar 

  67. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke. 2000;31(5):1062–8.

    Article  PubMed  CAS  Google Scholar 

  68. Olindo S, Cabre P, Deschamps R, Chatot-Henry C, Rene-Corail P, Fournerie P, et al. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique. French West Indies. Stroke. 2003;34(7):1593–7.

    Article  PubMed  CAS  Google Scholar 

  69. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98(5):476–84.

    Article  PubMed  CAS  Google Scholar 

  70. Kaste M, Palomaki H, Sarna S. Where and how should elderly stroke patients be treated? A randomized trial. Stroke. 1995;26(2):249–53.

    Article  PubMed  CAS  Google Scholar 

  71. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284(22):2901–6.

    Article  PubMed  CAS  Google Scholar 

  72. Mishra NK, Ahmed N, Andersen G, Egido JA, Lindsberg PJ, Ringleb PA, et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJs. 2010;341:c6046.

    Article  Google Scholar 

  73. Weimar C, Ziegler A, Konig IR, Diener HC. Predicting functional outcome and survival after acute ischemic stroke. J Neurol. 2002;249(7):888–95.

    Article  PubMed  Google Scholar 

  74. Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile AM, Wolfe CD, et al. Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke. 2003;34(5):1114–9.

    Article  PubMed  Google Scholar 

  75. Bagg S, Pombo AP, Hopman W. Effect of age on functional outcomes after stroke rehabilitation. Stroke. 2002;33(1):179–85.

    Article  PubMed  Google Scholar 

  76. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57(3):474–80.

    Article  PubMed  CAS  Google Scholar 

  77. Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy: sensitivity and specificity of cortical biopsy. Stroke. 1997;28(7):1418–22.

    Article  PubMed  CAS  Google Scholar 

  78. de Boer A, Kluft C, Kroon JM, Kasper FJ, Schoemaker HC, Pruis J, et al. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost. 1992;67(1):83–7.

    PubMed  Google Scholar 

  79. Neumann-Haefelin T, Hoelig S, Berkefeld J, Fiehler J, Gass A, Humpich M, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke. 2006;37(10):2463–6.

    Article  PubMed  Google Scholar 

  80. Vatankhah B, Dittmar MS, Fehm NP, Erban P, Ickenstein GW, Jakob W, et al. Thrombolysis for stroke in the elderly. J Thromb Thrombolysis. 2005;20(1):5–10.

    Article  PubMed  Google Scholar 

  81. Lindley RI, Wardlaw JM, Sandercock PA. Thrombolysis in elderly people: observational data insufficient to change treatment. BMJ. 2011;342:d306 (author reply d12).

  82. Berrouschot J, Rother J, Glahn J, Kucinski T, Fiehler J, Thomalla G. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke. 2005;36(11):2421–5.

    Article  PubMed  CAS  Google Scholar 

  83. Lyden PD. In anticipation of International Stroke Trial-3 (IST-3). Stroke. 2012;43(6):1691–4.

    Article  PubMed  Google Scholar 

  84. Lorenzano S, Toni D. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset. Int J Stroke. 2012;7(3):250–7.

    PubMed  Google Scholar 

  85. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457–507.

    Article  Google Scholar 

  86. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115(20):e478–534.

    Article  PubMed  Google Scholar 

  87. Tanne D, Gorman MJ, Bates VE, et al. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience. Stroke. 2000;31(2):370–5.

    Article  PubMed  CAS  Google Scholar 

  88. Chen CI, Iguchi Y, Grotta JC, et al. Intravenous TPA for very old stroke patients. Eur Neurol. 2005;54(3):140–4.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

There is no funding and no conflict of interest in connection with this manuscript.

Author information

Authors and Affiliations

  1. Department of Neurology, University Hospital of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland

    Hakan Sarikaya

  2. Department of Neurology, University Hospital of Berne, Berne, Switzerland

    Hakan Sarikaya

Authors
  1. Hakan Sarikaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hakan Sarikaya.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sarikaya, H. Safety and Efficacy of Thrombolysis with Intravenous Alteplase in Older Stroke Patients. Drugs Aging 30, 227–234 (2013). https://doi.org/10.1007/s40266-013-0052-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-013-0052-5

Keywords

Search

Navigation